Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Read the full articleYou might also wanna read
Eli Lilly's experimental GLP-1 drug achieves 28% average weight loss, raising safety questions
Eli Lilly is developing the the most powerful GLP-1 drug yet. But how much weight loss is too much?
washingtonpost.com·1mo ago
GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates
As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.
gizmodo.com·1mo ago
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
In this week’s Optimizer, we take a look at how health tech companies are starting to incorporate features ‘built for GLP-1’ users.
theverge.com·1mo ago
GLP-1 Drug Use Triples In Two Years As American Obesity Rate Falls, Gallup Finds
A new Gallup survey reveals that 11% of U.S. adults currently take GLP-1 medications for weight loss, a sharp rise from just 3% in 2024. The
3 High Growth GLP-1 Biotech Winners to Buy in July
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lowe
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow proc
Comments
Sign in to join the conversation.
No comments yet. Be the first.